Stock Report

Download full stock data and analysis for free Last Updated: 12-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Halozyme Therapeutics (HALO) Key Ratios

Stock Card factsheet share-fund-plan-icon

$107.53

up-down-arrow $0.53 (0.50%)

As on 11-Sep-2026 13:36EDT

Market cap

info icon

$12,506 Mln

Revenue (TTM)

info icon

$1,664 Mln

P/E Ratio

info icon

32.3

P/B Ratio

info icon

86.7

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 27.68 47.67 41.15 29.08 32.17
EBIT 56.32 38.77 -14.99 24.74 19.97
Net Profit 53.23 39.21 -25.78 20.96 12.58
EPS 55.32 42.59 -23.48 25.20 16.40
Book Value -- -- -85.24 -30.30 -16.80
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info 45.2247.6336.2834.7356.65
Net Margin info --62.9024.86----
Return on equity info 191.36183.15430.03153.59198.42
Return on Capital info 19.5424.59--15.6125.72
Return on Assets info 17.6522.9016.1913.8123.39
Debt to Equity (x) info ----13.5043.894.14

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
--
15.61
25.72
17.28
14.70
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

430.03

Higher than Peers by 470.36

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
430.03
153.59
198.42
222.07
110.23
Peer Median
-40.33
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

16.19

Higher than Peers by 47.43

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
16.19
13.81
23.39
15.75
13.72
Peer Median
-31.24
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

36.28

Higher than Peers by 118.88

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
36.28
34.73
56.65
44.27
40.28
Peer Median
-82.60
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

24.86

Higher than Peers by 116.16

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
24.86
22.69
43.74
33.96
30.70
Peer Median
-91.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
--
--
--
--
--
Peer Median
0.00
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

41.15

Lower than Peers by 12.88

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
41.15
0.38
0.22
0.26
0.49
Peer Median
54.03
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-14.99

Lower than Peers by 13.98

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
-14.99
-15.69
56.70
38.07
-3.64
Peer Median
-1.02
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-25.78

Lower than Peers by 18.25

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
-25.78
-28.64
57.71
39.31
-49.81
Peer Median
-7.53
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-23.48

Lower than Peers by 37.71

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
-23.48
-0.22
0.60
0.47
-0.48
Peer Median
14.23
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-55.81

Lower than Peers by 45.68

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
-55.81
--
--
--
--
Peer Median
-10.13
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

13.50

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
13.50
43.89
4.14
17.89
8.87
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

1.46

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
1.46
--
--
0.08
0.08
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

2.71

Lower than Peers by 3.10

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
2.71
4.66
7.80
6.64
5.65
Peer Median
5.81
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

2.31

Lower than Peers by 3.39

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
2.31
3.66
6.78
5.50
4.88
Peer Median
5.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

29.73

Higher than Peers by 31.82

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
29.73
26.76
31.79
19.57
15.69
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

27.40

Higher than Peers by 8.38

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
27.40
31.60
30.38
28.24
35.00
Peer Median
19.01
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.65

Higher than Peers by 0.59

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
0.65
0.61
0.53
0.46
0.45
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
--
98.04
97.61
102.47
89.10
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
--
190.34
308.69
216.20
201.93
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
--
18.62
25.28
28.02
25.22
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
--
269.75
381.02
290.65
265.81
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

32.31

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
32.31
24.99
13.93
17.20
39.02
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

86.71

Higher than Peers by 81.38

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
86.71
162.23
17.01
57.79
46.45
Peer Median
5.33
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

19.99

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
19.99
17.31
10.81
13.29
28.62
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

12,506

Higher than Peers by 12,365

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Halozyme Therapeutics (HALO)
12,506
--
--
--
--
Peer Median
142
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...